Investment analysts at StockNews.com started coverage on shares of Amarin (NASDAQ:AMRN - Get Free Report) in a research note issued to investors on Sunday. The firm set a "sell" rating on the biopharmaceutical company's stock.
Amarin Trading Up 0.9 %
AMRN traded up $0.00 during midday trading on Friday, hitting $0.53. 1,148,692 shares of the company were exchanged, compared to its average volume of 1,623,996. The company's 50 day simple moving average is $0.51 and its 200 day simple moving average is $0.60. The firm has a market capitalization of $217.00 million, a price-to-earnings ratio of -5.87 and a beta of 1.83. Amarin has a 1-year low of $0.43 and a 1-year high of $1.37.
Amarin (NASDAQ:AMRN - Get Free Report) last posted its earnings results on Wednesday, October 30th. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.02). Amarin had a negative return on equity of 7.22% and a negative net margin of 16.33%. The company had revenue of $42.30 million for the quarter, compared to analyst estimates of $43.82 million. During the same period last year, the business earned ($0.05) earnings per share. On average, equities analysts anticipate that Amarin will post -0.14 EPS for the current year.
Hedge Funds Weigh In On Amarin
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets raised its position in shares of Amarin by 8.8% in the third quarter. BNP Paribas Financial Markets now owns 1,301,468 shares of the biopharmaceutical company's stock valued at $816,000 after buying an additional 104,939 shares during the last quarter. Kornitzer Capital Management Inc. KS grew its stake in Amarin by 80.7% during the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 95,600 shares of the biopharmaceutical company's stock valued at $60,000 after acquiring an additional 42,700 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in Amarin by 63.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 76,959 shares of the biopharmaceutical company's stock valued at $48,000 after acquiring an additional 29,992 shares during the last quarter. Finally, Algert Global LLC purchased a new position in Amarin in the 2nd quarter worth approximately $34,000. 22.25% of the stock is owned by hedge funds and other institutional investors.
Amarin Company Profile
(
Get Free Report)
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Read More
Before you consider Amarin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amarin wasn't on the list.
While Amarin currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
